Enhanced accumulation of the isoprostane, 8-epi-PGF2α, in human aortic and pulmonary valves of patients with coronary heart disease

Histology and Histopathology

Volumn 17, Issue 4, 2002, Pages 1053-1059

  Mehrabi, Mohammad Reza ^a   Serbecic, N ^a   Ekmekcioglu, C ^a   Tamaddon, F ^a   Wild, T ^a   Plesch, K ^a   Sinzinger, H ^a   Glogar, H D ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atherosclerosis; Coronary heart disease; Isoprostane; Oxidative stress; Semilunar valves

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; CHOLESTEROL; ISOPROSTANE; TRIACYLGLYCEROL;

ADULT; AGED; AORTA VALVE; ARTICLE; ATHEROSCLEROSIS; BIOACCUMULATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; HUMAN TISSUE; ISCHEMIC HEART DISEASE; ISOLATED HEART; MALE; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PULMONARY VALVE; QUANTITATIVE HISTOCHEMISTRY; RADIOIMMUNOASSAY;

AGED; AORTIC VALVE; COLORING AGENTS; CORONARY DISEASE; DINOPROST; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; ISOPROSTANES; MALE; MIDDLE AGED; MYOCARDIUM; PULMONARY VALVE; RADIOIMMUNOASSAY;

EID: 0036789569     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Aronow W.S., Schwartz K.S. and Koenigsberg M. (1987). Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am. J. Cardiol. 59, 998-999.
2. Belov L., Meher-Homji V., Putaswamy V. and Miller R. (1999). Western blot analysis of bile or intestinal fluid from patients with septic shock or systemic inflammatory response syndrome, using antibodies to TNFα, IL-1α and IL-1β. Immunol. Cell Biol. 77, 34-40.
3. Davi G., Alessandrini P., Mezzetti A., Minotti G., Bucciarelli T., Costantini F., Cipollone F., Bon G.B., Ciabattoni G. and Patrono C. (1997). In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 17, 3230-3235.
4. Dibbs Z., Thornby J., White B.G. and Mann D.L. (1999). Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure, implications for clinical trials. J. Am. Coll. Cardiol. 33, 1935-1942.
5. Filip D.A., Vistor A., Bulla A., Rader A., Lupu F. and Simionescu M. (1987). Cellular events in the development of valvular atherosclerotic lesions induced by experimental hypercholesterolemia. Atherosclerosis 67, 199-204.
6. Gniwotta C., Morrow J.D., Roberts L.J. 2 nd and Kuhn H. (1997). Prostaglandin F2-like compounds, F2 isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 17, 3236-3241
7. Gotoh T., Kuroda T. and Yamasawa M. (1995). Correlation between lipoprotein (a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am. J. Cardiol. 76, 928-932.
8. Hughes H., Mathews B., Lenz M.L. and Guyton J.R. (1994). Cytotoxicity of oxidized LDL to porcine aortic smooth muscle cells is associated with the Oxysterols 7-Ketocholesterol and 7-Hydroxycholesterol. Arterioscler. Thromb. 14, 1177-1185.
9. Kim K.M. and Huang S.M. (1971). Ultrastructural study of calcification of human aortic valve. Lab. Invest. 25, 357-364.
10. Liu T., Stern A., Roberts L.J. and Morrow J.D. (1999). The isoprostanes, Novel prostaglandin-like products of the free radical-catalyzed peroxidation of arachidonic acid. J. Biomed. Sci. 6, 226-235.
11. Martin T.R. (1999). Lung cytokines and ARDS, Roger S. Mitchell Lecture. Chest 116, 2S-8S.
12. 2α, is accumulated in coronary arteries isolated from patients with coronary heart disease. Cardiovasc. Res. 43, 492-499.
13. Mehrabi M.R., Sinzinger H., Ekmekcioglu C., Tamaddon F., Plesch K., Glogar H.D., Maurer G., Stefenelli T. and Lang I.M. (2000). Accumulation of oxidized LDL in human semilunar valves correlates with coronary atherosclerosis. Cardiovasc. Res. 45, 874-882.
14. Mohler E.R., Sheridan M.J., Nichols R., Harvey W.P. and Waller B.F. (1991). Development and progression of aortic valve stenosis, atherosclerotic risk factors - a causal relationship? A clinical morphologic study. Clin. Cardiol. 14, 995-999.
15. Morrow J.D., Hill K.E., Burk R.F., Nammour T.M., Badr K.F. and Robert L.J. 2nd (1990). A series of prostaglandin F2 -like compounds are produced in-vivo in humans by a non-cyclooxygenase, free radical - catalyzed mechanism. Proc. Natl. Acad. Sci. USA 87, 9383-9387.
16. Nievelstein-Post P., Mottino G., Fogelman A. and Frank J. (1994). An ultrastructural study of lipoprotein accumulation in cardiac valves of the rabbit. Arterioscler. Thromb. 14, 1151-1161.
17. 2α, in heterozygous hypercholesterolemia. Wien. Klin. Wochenschr. 111, 113-118.
18. Otto C.M., Lind B.K., Kitzman D.W., Gersh B.J. and Siscovick D.S. (1999). Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N. Engl. J. Med. 341, 142-147.
19. Patrono C. and FitzGerald G.A. (1997). Isoprostanes. Potential markers of oxidant stress in atherothrombotic disease. Arterioscler. Thromb. Vasc. Biol. 17, 2309-2315.
20. Pratico D., Iuliano L., Mauriello A., Spagnoli L., Lawson J.A., Rokach J., Maclouf J., Violi F. and FitzGerald G.A. (1997). Localization of distinct F-2-isoprostanes in human atherosclerotic lesions. J. Clin. Invest. 100, 2028-2034.
21. Simionescu N., Vasile E., Lupu F., Popescu G. and Simionescu M. (1986). Prelesional events in atherogenesis. Am. J. Pathol. 123, 109-125.
22. Thurbrikar M.J., Deck Y.D., Aouad J. and Chen Y.M. (1985) Internal stress as a causative factor in atherosclerotic lesions of the aortic valve. Atherosclerosis 55, 299-311.
23. Walton K.W., Williamson M. and Johnson A.G. (1970) The pathogenesis of atherosclerosis of the mitral valves. J. Pathol. 101, 205-220.
24. 2α excretion in man J. Pharmacol. Exp. Ther. 275, 94-100.
25. Zahor Z. and Czabanova V. (1977). Experimental atherosclerosis of the heart valves in rat following long-term atherogenic regimen. Atherosclerosis 27, 49-59.